2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
21
Carcinoma, Non-Small-Cell Lung
21
Breast Neoplasms
20
Neoplasms
19
Stomach Neoplasms
15
Colorectal Neoplasms
15
Lung Neoplasms
13
Endometrial Neoplasms
13
Pancreatic Neoplasms
11
Leukemia, Myeloid, Acute
10
Colonic Neoplasms
9
Carcinoma, Hepatocellular
9
Melanoma
7
Oropharyngeal Neoplasms
6
Neoplasm Metastasis
6
Multiple Myeloma
6
Lymphoma, Large B-Cell, Diffuse
6
Esophageal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Rectal Neoplasms
5
Mouth Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Head and Neck Neoplasms
5
Uterine Cervical Neoplasms
4
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Observation
×
Clear all
NCT04442048
2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3
Completed
195 enrolled